Where does Emcure Pharmaceuticals Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Emcure Pharmaceuticals Limited ranks #18,577 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Emcure Pharmaceuticals Limited hold?

Emcure Pharmaceuticals Limited holds 15 US utility patents granted between 2015 and 2025, spanning 8 technology areas.

What is Emcure Pharmaceuticals Limited's Innovation Score?

Emcure Pharmaceuticals Limited has an Innovation Score of 27.7 out of 100 (25th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Emcure Pharmaceuticals Limited focus on?

Emcure Pharmaceuticals Limited's top technology area is C07D (Heterocyclic Compounds) with 7 patents, ranking #1,096 of 3,165 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Emcure Pharmaceuticals Limited's patent grant rate increasing or decreasing?

Emcure Pharmaceuticals Limited's recent grant velocity is -60% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Emcure Pharmaceuticals Limited's patents?

Emcure Pharmaceuticals Limited's patents average 10.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Emcure Pharmaceuticals Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Emcure Pharmaceuticals Limited

USPTO PatentsView assignee record - 15 granted patents across 8 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Emcure ranks #18,577 of 49,997 tracked US assignees by granted-patent volume, with 15 patents across 8 technology areas.

#18,577
of 49,997 US assignees by volume: 25th percentile
by Innovation Score (27.7/100): 10.8
avg claims per patent: -60%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R18577 · Foreign Corporation #18,577 · 15 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 15 grants
MID-PACK #18,577/49,997
PHOTO-FINISH Eitan Medical
CPC-NARROW C07D · 8 areas
INNOV-THIN 27.7/100
CLAIMS-PAR 10.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -60% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Eitan Medical Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Emcure’s 27.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.6 pts (35%) Velocity 1.7 pts (6%) Breadth 10.0 pts (36%) Claim depth 6.5 pts (23%)

Qualcomm Incorporated · highest

85
Emcure Pharmaceuticals · this assignee

28
3D Lighting… · lowest

7

What this shows Emcure's Innovation Score is 27.7/100 (25th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Emcure?

Each dot is one of Emcure’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Emcure’s own 10.8 claims/patent is at or below the 11.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Emcure vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Emcure's grants concentrate

Emcure Pharmaceuticals Limited is a focused PatentsView assignee: 8 CPC subclasses with 46.7% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2016 (5 grants) versus a trough of 1 in 2017. By volume, Emcure sits between Eitan Medical Ltd. and Enlivex Therapeutics R&D Ltd.

Emcure's three-year grant acceleration

Emcure Pharmaceuticals Limited shows 1 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Eitan Medical

15
Eltek AS

15
Emak S P A

15
Embodyvr

15
Emergex Vaccines…

15
Eneos Materials

15
Enermax Technology

15
Enlivex Therapeut…

15
Emcure Pharmaceut… ◀

15

What this shows Emcure holds 15 patents at rank #18,567, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Emcure

By rank, the assignees closest to #18,567 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Emcure's primary technology class.

Emcure's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 25th percentile higher than 25% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Emcure Pharmaceuticals Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	13.3%
2016	5	33.3%
2017	1	6.7%
2018	1	6.7%
2019	1	6.7%
2020	3	20.0%
2024	1	6.7%
2025partial year	1	6.7%

Which technologies does Emcure Pharmaceuticals Limited patent most?

C07D - Heterocyclic Compounds 7

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

C07C - Acyclic OR Carbocyclic Compounds 5

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 5

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 3

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Emcure Pharmaceuticals Limited's patent record in context - here's where to go next.

Emcure Pharmaceuticals Limited's lead technology class is C07D (Heterocyclic Compounds), 46.7% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #18,577 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Emcure Pharmaceuticals Limited against Eitan Medical Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 27.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.